These results demonstrate that iRGD NPs@si‐SOX9/CL accumulate efficiently in tumor tissues, inhibit tumor growth by suppressing the SOX9/TIMP1/PI3K axis, and promote DC activation and maturation, thereby achieving potent immunotherapeutic efficacy. This evidence concerns the gene SOX9 and neoplasm.